CisplatinExtraAlternative Names: CiplatinExtra; Cisplatin - SuperGen
Latest Information Update: 26 Feb 2009
At a glance
- Originator SuperGen
- Class Antineoplastics; Platinum complexes
- Mechanism of Action DNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 23 Nov 2001 CisplatinExtra is still in active development
- 25 Jan 1999 Preclinical development for Cancer in USA (Unknown route)